Skip to main content
SpringerLink
Log in

Thiazide-Like/Calcium Channel Blocker Agents: A Major Combination for Hypertension Management

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

An Erratum to this article was published on 08 January 2015

Abstract

In recent years, treatment strategies for hypertension have often focused on combination therapies that include diuretics and renin angiotensin aldosterone system blockers such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. However, in clinical practice, a significant number of patients do not respond completely to these combination treatments, and long-term reduction of cardiovascular risk remains insufficient. The particularly high residual cardiovascular risk of hypertensive patients, even when adequately treated with strategies based on renin angiotensin aldosterone system blockers, speaks in favor of new, innovative strategies. Thus, it has become relevant to consider whether it is always necessary to block plasma renin activation and whether other guideline-approved combinations should be considered routinely. Diuretic/calcium channel blocker combinations, which are supported by significant long-term evidence, are put forth as a preferred combination in the main guidelines, but are still underused by physicians who do not yet have easy access to such treatments. Fixed-dose indapamide sustained release/amlodipine is the first such single-pill combination to become available. Complementary mechanisms of action of these two molecules are expected to lead to greater and longer-term reductions in systolic blood pressure and pulse pressure and potentially to the reduction of cardiovascular risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126(17):2105–14. doi:10.1161/CIRCULATIONAHA.112.096156.

    Article  CAS  PubMed  Google Scholar 

  2. Thomas F, Pannier B, Safar ME. Impact of country of birth on progression of steady and pulsatile hemodynamic parameters in normotensive and hypertensive subjects. J Am Soc Hypertens. 2013;7(6):440–7. doi:10.1016/j.jash.2013.07.005.

    Article  PubMed  Google Scholar 

  3. Blacher J, Evans A, Arveiler D, Amouyel P, Ferrieres J, Bingham A, et al. Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study. J Hum Hypertens. 2010;24(1):19–26. doi:10.1038/jhh.2009.34.

    Article  CAS  PubMed  Google Scholar 

  4. Tocci G, Rosei EA, Ambrosioni E, Borghi C, Ferri C, Ferrucci A, et al. Blood pressure control in Italy: analysis of clinical data from 2005–2011 surveys on hypertension. J Hypertens. 2012;30(6):1065–74. doi:10.1097/HJH.0b013e3283535993.

    Article  CAS  PubMed  Google Scholar 

  5. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103(9):1245–9.

    Article  CAS  PubMed  Google Scholar 

  6. Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291–7.

    Article  CAS  PubMed  Google Scholar 

  7. Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu L, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med. 2000;160(8):1085–9.

    Article  CAS  PubMed  Google Scholar 

  8. Safar ME, Nilsson PM. Pulsatile hemodynamics and cardiovascular risk factors in very old patients: background, sex aspects and implications. J Hypertens. 2013;31(5):848–57. doi:10.1097/HJH.0b013e32835ed5b9.

    Article  CAS  PubMed  Google Scholar 

  9. National Clinical Guideline Centre. Hypertension. Clinical management of primary hypertension in adults (NICE clinical guideline 127). London, 2011.

  10. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014;23(1):3–16. doi:10.3109/08037051.2014.868629.

    Article  PubMed  Google Scholar 

  11. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ. 2013;346:f360. doi:10.1136/bmj.f360.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Bohm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens. 2010;24(5):336–44. doi:10.1038/jhh.2009.76.

    Article  CAS  PubMed  Google Scholar 

  13. Olson N, DeJongh B, Hough A, Parra D. Plasma renin activity-guided strategy for the management of hypertension. Pharmacotherapy. 2012;32(5):446–55. doi:10.1002/j.1875-9114.2012.01031.x.

    Article  CAS  PubMed  Google Scholar 

  14. Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, et al. An effective approach to high blood pressure control: a science advisory from the American heart association, the American college of cardiology, and the centers for disease control and prevention. Hypertension. 2014;63(4):878–85. doi:10.1161/HYP.0000000000000003.

    Article  CAS  PubMed  Google Scholar 

  15. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.

    Article  PubMed  Google Scholar 

  16. Sealey JE, Alderman MH, Furberg CD, Laragh JH. Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels. Am J Hypertens. 2013;26(6):727–38. doi:10.1093/ajh/hpt034.

    Article  CAS  PubMed  Google Scholar 

  17. Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J. 2011;32(20):2499–506. doi:10.1093/eurheartj/ehr177.

    Article  PubMed  Google Scholar 

  18. Suonsyrja T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Donner K, Strandberg T, et al. Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. J Hypertens. 2008;26(6):1250–6. doi:10.1097/HJH.0b013e3282fcc37f.

    Article  CAS  PubMed  Google Scholar 

  19. Schwartz GL, Bailey K, Chapman AB, Boerwinkle E, Turner ST. The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension. Am J Hypertens. 2013;26(8):957–64. doi:10.1093/ajh/hpt047.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293(13):1595–608. doi:10.1001/jama.293.13.1595.

    Article  CAS  PubMed  Google Scholar 

  21. Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens. 2001;14(3):241–7 (S0895-7061(00)01266-8 [pii]).

    Article  CAS  PubMed  Google Scholar 

  22. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106(19):2422–7.

    Article  CAS  PubMed  Google Scholar 

  23. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23(12):2157–72 00004872-200512000-00008 [pii].

    Article  CAS  PubMed  Google Scholar 

  24. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–31.

    Article  CAS  PubMed  Google Scholar 

  25. Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011;29(8):1649–59. doi:10.1097/HJH.0b013e328348345d.

    Article  CAS  PubMed  Google Scholar 

  26. Wang W, Ma L, Zhang Y, Liu M, Deng Q, Zhu D, et al. 4 years outcome of amlodipine plus telmisartan or amlodipine plus diuretics regimen on cardiovascular events in hypertensive patients 13,542: final results of CHIEF trial. In: Hypertension ESo, editor. 23rd European Meeting on Hypertension and Cardiovascular Protection, Milan, Italy; 2013.

  27. DiNicolantonio JJ. Hydrochlorothiazide: is it a wise choice? Expert Opin Pharmacother. 2012;13(6):807–14. doi:10.1517/14656566.2012.670636.

    Article  CAS  PubMed  Google Scholar 

  28. Musini VM, Nazer M, Bassett K, Wright JM. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;5:CD003824. doi:10.1002/14651858.CD003824.pub2.

    PubMed  Google Scholar 

  29. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82(5):1616–1628.

  30. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.

    Article  CAS  PubMed  Google Scholar 

  31. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28.

    Article  CAS  PubMed  Google Scholar 

  32. Waeber B, Rotaru C, Feihl F. Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. Expert Opin Pharmacother. 2012;13(10):1515–26. doi:10.1517/14656566.2012.698611.

    Article  CAS  PubMed  Google Scholar 

  33. Plante GE, Dessurault DL. Hypertension in elderly patients. A comparative study between indapamide and hydrochlorothiazide. Am J Med. 1988;84(1B):98–103.

    Article  CAS  PubMed  Google Scholar 

  34. Carretta R, Fabris B, Bardelli M, Muiesan S, Fischetti F, Vran F, et al. Arterial compliance and baroreceptor sensitivity after chronic treatment with indapamide. J Hum Hypertens. 1988;2(3):171–5.

    CAS  PubMed  Google Scholar 

  35. London G, Schmieder R, Calvo C, Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. Am J Hypertens. 2006;19(1):113–21. doi:10.1016/j.amjhyper.2005.06.027.

    Article  CAS  PubMed  Google Scholar 

  36. Agnoletti D, Zhang Y, Borghi C, Blacher J, Safar ME. Effects of antihypertensive drugs on central blood pressure in humans: a preliminary observation. Am J Hypertens. 2013;26(8):1045–52. doi:10.1093/ajh/hpt081.

    Article  CAS  PubMed  Google Scholar 

  37. Ma F, Lin F, Chen C, Cheng J, Zeldin DC, Wang Y, et al. Indapamide lowers blood pressure by increasing production of epoxyeicosatrienoic acids in the kidney. Mol Pharmacol. 2013;84(2):286–95. doi:10.1124/mol.113.085878.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Vergely C, Walker MK, Zeller M, Rademakers JR, Maupoil V, Schiavi P, et al. Antioxidant properties of indapamide, 5-OH indapamide and hydrochlorothiazide evaluated by oxygen-radical absorbing capacity and electron paramagnetic resonance. Mol Cell Biochem. 1998;178(1–2):151–5.

    Article  CAS  PubMed  Google Scholar 

  39. Et-Taouil K, Schiavi P, Levy BI, Plante GE. Sodium intake, large artery stiffness, and proteoglycans in the spontaneously hypertensive rat. Hypertension. 2001;38(5):1172–6.

    Article  CAS  PubMed  Google Scholar 

  40. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003;23(12):2155–63. doi:10.1161/01.ATV.0000097770.66965.2A.

    Article  CAS  PubMed  Google Scholar 

  41. Cappuccio FP, Markandu ND, Sagnella GA, Singer DR, Buckley MG, Miller MA, et al. Effects of amlodipine on urinary sodium excretion, renin-angiotensin-aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertension. J Hum Hypertens. 1991;5(2):115–9.

    CAS  PubMed  Google Scholar 

  42. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102(13):1503–10.

    Article  CAS  PubMed  Google Scholar 

  43. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217–25.

    Article  CAS  PubMed  Google Scholar 

  44. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–25. doi:10.1161/CIRCULATIONAHA.105.595496.

    Article  CAS  PubMed  Google Scholar 

  45. Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Clin Drug Investig. 2007;27(11):735–53 (27111 [pii]).

    Article  CAS  PubMed  Google Scholar 

  46. Emeriau JP, Knauf H, Pujadas JO, Calvo-Gomez C, Abate G, Leonetti G, et al. A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens. 2001;19(2):343–50.

    Article  CAS  PubMed  Google Scholar 

  47. Akram J, Sheikh UE, Mahmood M, Donnelly R. Antihypertensive efficacy of indapamide SR in hypertensive patients uncontrolled with a background therapy: the NATIVE study. Curr Med Res Opin. 2007;23(12):2929–36. doi:10.1185/030079907X242674.

    Article  CAS  PubMed  Google Scholar 

  48. Hanon O, Asmar R, Marre M, editors. Benefit of adding amlodipine 5 mg and 10 mg to indapamide SR in uncontrolled hypertensive patients with diabetes mellitus. Results of the 1-year NESTOR trial (abstract). 23rd scientific meeting of the European Society of Hypertension, Milan, Italy; 2013.

  49. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlof B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375(9718):895–905. doi:10.1016/S0140-6736(10)60308-X.

    Article  PubMed  Google Scholar 

  50. Zhang Y, Agnoletti D, Safar ME, Blacher J. Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension. 2011;58(2):155–60. doi:10.1161/HYPERTENSIONAHA.111.174383.

    Article  CAS  PubMed  Google Scholar 

  51. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlof B, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9(5):469–80. doi:10.1016/S1474-4422(10)70066-1.

    Article  CAS  PubMed  Google Scholar 

  52. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Gueret P, Karpov Y, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens. 2000;18(10):1465–75.

    Article  CAS  PubMed  Google Scholar 

  53. Kloner RA, Sowers JR, DiBona GF, Gaffney M, Wein M. Effect of amlodipine on left ventricular mass in the Amlodipine Cardiovascular Community Trial. J Cardiovasc Pharmacol. 1995;26(3):471–6.

    Article  CAS  PubMed  Google Scholar 

  54. Marre M, Puig JG, Kokot F, Fernandez M, Jermendy G, Opie L, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens. 2004;22(8):1613–22.

    Article  CAS  PubMed  Google Scholar 

  55. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088–97. doi:10.1093/eurheartj/ehs075.

    Article  PubMed Central  PubMed  Google Scholar 

  56. Tepel M, Hopfenmueller W, Scholze A, Maier A, Zidek W. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transpl. 2008;23(11):3605–12. doi:10.1093/ndt/gfn304.

    Article  CAS  Google Scholar 

  57. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl). 1995;108(9):710–7.

    Google Scholar 

  58. Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. Hypertension. 2007;50(1):181–8. doi:10.1161/HYPERTENSIONAHA.107.089763.

    Article  CAS  PubMed  Google Scholar 

  59. PROGRESS Collaborative group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033–41.

    Article  Google Scholar 

  60. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59(6):1124–31. doi:10.1161/HYPERTENSIONAHA.112.194167.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  62. Jadhav U, Hiremath J, Namjoshi DJ, Gujral VK, Tripathi KK, Siraj M, et al. Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study. PLoS One. 2014;9(4):e92955. doi:10.1371/journal.pone.0092955.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors received honoraria or research Grants from Servier. The authors have no other relevant affiliations or financial involvement with any organization or entity in conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Author information

Authors and Affiliations

  1. Centre de Diagnostic et de Thérapeutique, Hôpital Hotel Dieu, 1 Place du Parvis Notre Dame, 75004, Paris, France

    M. E. Safar & J. Blacher

Authors
  1. M. E. Safar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Blacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. E. Safar.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Safar, M.E., Blacher, J. Thiazide-Like/Calcium Channel Blocker Agents: A Major Combination for Hypertension Management. Am J Cardiovasc Drugs 14, 423–432 (2014). https://doi.org/10.1007/s40256-014-0087-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-014-0087-y

Keywords

Search

Navigation